Triazavirin-A Novel Effective Antiviral Drug

被引：22

作者：

Chupakhin, Oleg N. ^{[1
,2
]}

Rusinov, Vladimir L. ^{[1
,2
]}

Varaksin, Mikhail V. ^{[1
,2
]}

Ulomskiy, Evgeny N. ^{[1
,2
]}

Savateev, Konstantin V. ^{[1
]}

Butorin, Ilya I. ^{[1
]}

Du, Weijie ^{[3
]}

Sun, Zhiyong ^{[3
]}

Charushin, Valery N. ^{[1
,2
]}

机构：

[1] Ural Fed Univ, Inst Chem Engn, Dept Organ & Biomol Chem, Ekaterinburg 620002, Russia

[2] Russian Acad Sci, Inst Organ Synth, Ural Branch, Ekaterinburg 620990, Russia

[3] Harbin Med Univ, Coll Pharm, Dept Pharmacol, Key Lab Cardiovasc Res,Minist Educ, Harbin 150086, Peoples R China

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2022年 / 23卷 / 23期

关键词：

triazavirin; riamilovir; SARS-CoV-2; COVID-19; antiviral therapy; FOREST-SPRING ENCEPHALITIS; ETIOTROPIC THERAPY; RIAMILOVIR EFFICACY; CLINICAL-TRIALS; INFLUENZA-A; PHARMACOKINETICS; METAANALYSIS; INFECTION; VIRUS;

D O I：

10.3390/ijms232314537

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

This review outlines the data of numerous studies relating to the broad-spectrum antiviral drug Triazavirin that was launched on the Russian pharmaceutical market in 2014 as an anti-influenza drug (the international non-patented name is Riamilovir). The range of antiviral activity of Triazavirin has been significantly expanded during recent years; in particular, it has been shown that Triazavirin exhibits activity against tick-borne encephalitis, Rift Valley fever, West Nile fever, and other infections of viral etiology. This drug has been approved for treatment of influenza and acute respiratory infections by the Russian Ministry of Health on the basis of comprehensive clinical trials involving over 450 patients. Triazavirin was found to be a highly effective and well-tolerated drug, allowing its over-the-counter sale. The recently published data on the use of Triazavirin in clinical practice for the treatment of patients with COVID-19 are discussed, with special attention paid to potential biological targets for this drug.

引用

页数：18

共 86 条

[1] Hypothetical targets and plausible drugs of coronavirus infection caused by SARS-CoV-2 [J].

Almasi, Faezeh ;

Mohammadipanah, Fatemeh .

TRANSBOUNDARY AND EMERGING DISEASES, 2021, 68 (02) :318-332

[2]

Blazhennikova I. V., 2015, Eksperimental'naya i Klinicheskaya Farmakologiya, V78, P34

[3] In silico evaluation of potential inhibitory activity of remdesivir, favipiravir, ribavirin and galidesivir active forms on SARS-CoV-2 RNA polymerase [J].

Celik, Ismail ;

Erol, Meryem ;

Duzgun, Zekeriya .

MOLECULAR DIVERSITY, 2022, 26 (01) :279-292

[4]

Chepur Sergey V, 2021, Antibiotiki i Khimioterapiya, V66, P13, DOI 10.37489/0235-2990-2021-66-7-8-13-19

[5] Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening [J].

Chtita, Samir ;

Belhassan, Assia ;

Aouidate, Adnane ;

Belaidi, Salah ;

Bouachrine, Mohammed ;

Lakhlifi, Tahar .

COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, 2021, 24 (03) :441-454

[6] Scientific foundations for the creation of antiviral and antibacterial preparations [J].

Chupakhin, O. N. ;

Charushin, V. N. ;

Rusinov, V. L. .

HERALD OF THE RUSSIAN ACADEMY OF SCIENCES, 2016, 86 (03) :206-212

[7]

Chupakhin O.N., 2009, Patent, Patent No. 2343154

[8]

Chupakhin O.N., 2017, Patent, Patent No. [EA026688, 026688]

[9]

Chupakhin O.N., 2007, RF Patent, Patent No. 2294936

[10]

Chupakhin O.N., 2013, Patent, Patent No. 2013122575

← 1 2 3 4 5 6 7 8 9 →